Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021
HomeCatalyst OrthoScience Inc.Catalyst CSR Total Shoulder System Published Study Results

Catalyst CSR Total Shoulder System Published Study Results

Catalyst CSR Total Shoulder System published study results, (Journal of Shoulder and Elbow Surgery, demonstrates good results in adult arthroplasty patients of all ages at 2-3 year follow-up.

Show positive data around the use of the Catalyst CSR™ Total Shoulder System in adult arthroplasty patients of all ages, rather than just younger patients. The retrospective case series examines the initial cohort of patients that received an anatomic total shoulder arthroplasty (TSA) using the Catalyst CSR system from August 2016 to August 2017. Patients were evaluated at multiple time points postoperatively with a minimum of two-year follow-up.

The selection criteria of patients were broad and included all patients with “glenohumeral joint arthritis with an intact rotator cuff, regardless of patient age.” No cases in this continuous series of patients were converted to a stemmed TSA device intraoperatively due to bone quality. This has not been the case in previous studies for stemless implants,1 and may be attributed to the unique, patented design of the Catalyst CSR humeral implant. This is also the first study to report clinical outcomes using an ellipsoid-shaped humeral head implant, which better resembles the native humeral shape and has been shown to perform superiorly in biomechanical studies.2, 3 Catalyst OrthoScience is the first orthopedic company to offer ellipsoid implants to patients.

Highlights of the study include:

  • At a two-year minimum follow-up, a TSA using the stemless, ellipsoid Catalyst CSR system provided positive results, with statistically significant and clinically meaningful improvements in all range of motion outcomes, high patient satisfaction and no signs of loosening.
  • Sixty-three shoulders in 57 patients with a mean age of 73 years (range of 60-85 years old) were included in the study. While stemless shoulder designs have been previously thought to be better suited only for younger patients, this cohort represents a wider age population than groups that were previously studied. This study provides evidence that the stemless, ellipsoid Catalyst CSR system may be used safely in adult arthroplasty patients of all ages with good clinical outcomes.
  • Patient-reported outcomes showed statistically significant improvements preoperatively to postoperatively, exceeding the minimal clinically important difference (MCID) and substantial clinical benefit (SCB). Several of these milestones were achieved for patients as early as six weeks postoperatively and at all time points thereafter.
  • There was a low rate of complications and no implant failures in this study group.

“This study is the first to report on clinical results with an ellipsoid implant used in shoulder arthroplasty,” said Theodore A. Blaine, MD, sports medicine surgeon at Hospital for Special Surgery (HSS), and professor of orthopedic surgery at Weill Cornell Medical College. “The Catalyst CSR system’s ellipsoid-shaped articular surface and unique multiplanar, stemless fixation that rests on dense subchondral bone is shown not only to be safe and effective for patients of a wide range of ages, but also provides significant clinical improvement in all outcome measures studied.”

“The data demonstrates that the patients not only do very well, but do so quickly, with most measures reaching the benchmark of substantial clinical benefit by six weeks,” said Steven Goldberg, MD, lead author on the study. “This is likely due to the bone preserving procedure and less dissection required to insert the Catalyst CSR replacement.”

Designed by surgeons for surgeons, the Catalyst CSR system represents the next evolution in shoulder surgery. The system’s humeral implant is engineered to accurately replace the elliptical shape of the patient’s native non-spherical humeral head. The simple surgical technique creates a unique, multiplanar chamfer cut geometry on the humeral head that minimizes bone removal and preserves the strongest, densest bone for the humeral component fixation – similar to modern knee replacement.

Patented, angled glenoid instruments aid in the glenoid exposure and lessen retraction on the soft tissue. The precision of the system’s unique instrumented technique and implant design yields highly accurate and repeatable restoration of the native humeral anatomy. The system’s single tray design is easily adaptable for both hospital and ambulatory surgery center procedures. These benefits position the Catalyst CSR system as an attractive solution for anatomic total shoulder replacement surgery.


References:

  1. Churchill RS, Chuinard C, Wiater JM, Friedman R, Freehill M, Jacobson S et al. Clinical and Radiographic Outcomes of the Simpliciti Canal-Sparing Shoulder Arthroplasty System: A Prospective Two-Year Multicenter Study. J Bone Joint Surg Am 2016;98:552-560. 10.2106/JBJS.15.00181
  2. Jun BJ, Iannotti JP, McGarry MH, Yoo JC, Quigley RJ, Lee TQ. The effects of prosthetic humeral head shape on glenohumeral joint kinematics: a comparison of non-spherical and spherical prosthetic heads to the native humeral head. J Shoulder Elbow Surg 2013;22:1423-1432. 10.1016/j.jse.2013.01.002
  3. Jun BJ, Lee TQ, McGarry MH, Quigley RJ, Shin SJ, Iannotti JP. The effects 500 of prosthetic humeral head shape on glenohumeral joint kinematics during humeral axial rotation in total shoulder arthroplasty. J Shoulder Elbow Surg 2016;25:1084-1093. 10.1016/j.jse.2015.11.058
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy